Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed360%
active_not_recruiting120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Two Chemotherapy Regimens Plus or Minus Bevacizumab

NCT03351296
terminatedphase_2

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

NCT00609765
completedphase_2

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

NCT00004688
completedphase_2

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

NCT00602082
completedphase_1

Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00003543

Clinical Trials (5)

Showing 5 of 5 trials
NCT03351296Phase 2

Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active Not Recruiting
NCT00609765Phase 2

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Terminated
NCT00004688Phase 2

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

Completed
NCT00602082Phase 2

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Completed
NCT00003543Phase 1

Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5